Back to results
US 2011/0256223 A1Published application
Gastric retained gabapentin dosage form
AssigneeDepomed, Inc.
InventorsBRET BERNER, Sui Yuen Eddie Hou, Gloria M. Gusler
Life of this patent
Estimating the term…
Abstract
A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.
Claims23
A dosage form, comprising:
- a matrix comprising a dose of gabapentin, wherein upon once-daily or twice daily ingestion of the dosage form gabapentin is released from the matrix at a rate sufficient to achieve a maximum plasma concentration (Cmax) of at least about 3 μg/mL.
A dosage form, comprising:
- a matrix comprising a 300 mg or a 600 mg dose of gabapentin, wherein upon ingestion once-daily of one 600 mg dosage form or upon ingestion of two 300 mg dosage forms, gabapentin is released from the matrix at a rate sufficient to achieve a maximum plasma concentration (Cmax) of at least about 3 μg/mL.
A method of treating a condition responsive to a therapeutic dose of gabapentin, comprising:
- orally administering once-daily or twice daily a dosage form comprising a matrix comprising a dose of gabapentin, whereby the dosage form releases gabapentin at a rate sufficient to achieve a maximum plasma concentration (Cmax) of at least about 3 μg/ml.
Dependencies are inferred from the claim text.